-transparent.png){kind=logo}
Monoclonal antibodies to small cell lung cancer (SCLC) were produced by fusion of P3X63/AgU1 mouse myeloma cells with spleen cells from BALB/c mice immunized against intact cells of SCLC tumors grown in BALB/c athymic nude mice. The antibody TFS-2 demonstrated "pancarcinoma" reactivity showing binding to non-small cell lung cancer (NSCLC) and carcinomas derived from other organs such as stomach, pancreas, and colon. This antibody failed to react with a variety of normal tissues including lung, bone marrow, spleen, stomach, colon, and pancreas. TFS-2 showed complement-mediated cytolysis of target cells. TFS-2 had no significant effects on hematopoietic stem cells. This antibody will serve as a powerful tool for the in vitro removal of tumor cells from bone marrow, thus facilitating high-dose chemotherapy of SCLC with autologous bone marrow transplantation. In contrast, TFS-4 monoclonal antibody reacted specifically with SCLC but not with NSCLS tumors. This antibody can distinguish SCLC from NSCLC tumors in histologic diagnosis at transbronchial biopsy, and in cytological identification of tumor cells in malignant effusion, and in infiltrated bone marrow. Radiolabeled TSF-4 specifically accumulated into SCLC tumors that were implanted subcutaneously into athymic nude mice. Thus, the antibody will be useful not only for diagnosis of lung cancer but also for targeting anti-tumor agents.
T Okabe, and
T Kaizu, and
M Fujisawa, and
J Watanabe, and
F Takaku
September 1991,
Biulleten' eksperimental'noi biologii i meditsiny,
T Okabe, and
T Kaizu, and
M Fujisawa, and
J Watanabe, and
F Takaku
September 2009,
Journal of B.U.ON. : official journal of the Balkan Union of Oncology,
T Okabe, and
T Kaizu, and
M Fujisawa, and
J Watanabe, and
F Takaku
June 1988,
Shi yan sheng wu xue bao,
T Okabe, and
T Kaizu, and
M Fujisawa, and
J Watanabe, and
F Takaku
April 1988,
Gan to kagaku ryoho. Cancer & chemotherapy,
T Okabe, and
T Kaizu, and
M Fujisawa, and
J Watanabe, and
F Takaku
July 1983,
Journal of immunology (Baltimore, Md. : 1950),
T Okabe, and
T Kaizu, and
M Fujisawa, and
J Watanabe, and
F Takaku
March 2013,
Targeted oncology,
T Okabe, and
T Kaizu, and
M Fujisawa, and
J Watanabe, and
F Takaku
October 2011,
Critical reviews in oncology/hematology,
T Okabe, and
T Kaizu, and
M Fujisawa, and
J Watanabe, and
F Takaku
January 1986,
Cancer,
T Okabe, and
T Kaizu, and
M Fujisawa, and
J Watanabe, and
F Takaku
January 1993,
Medicinski pregled,
T Okabe, and
T Kaizu, and
M Fujisawa, and
J Watanabe, and
F Takaku
December 2012,
Translational lung cancer research,
